inclusion criteria: * is a male or female greater than or equal to18 years of age at screening; * is willing and able to sign and date (or has a legally authorized representative willing to sign and date) a written (or electronic) informed consent form or provide equivalent consent per food and drug administration guidelines on covid-19 clinical trials; * has a documented, laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection as determined by polymerase chain reaction, a sars-cov-2 antigen test, or another commercial or public health assay, within 3 days (72 hours) of randomization; * has covid-19 of moderate severity, as defined by the following: positive testing by standard reverse transcription polymerase chain reaction assay or equivalent testing; symptoms of illness with covid-19, which could include any of the following: cough, fever, shortness of breath, chest pain, abdominal pain, nausea/vomiting, diarrhea, body aches, weakness/fatigue, or new loss of taste or smell; clinical signs suggestive of illness with covid-19, such as respiratory rate greater than or equal to 20 breaths per minute, saturation of oxygen greater than 93% on room air at sea level, or heart rate greater than or equal to 90 beats per minute; and no clinical signs indicative of severe or critical severity.

inclusion criteria: * is a male or female greater than or equal to18 years of age at screening; * is willing and able to sign and date (or has a legally authorized representative willing to sign and date) a written (or electronic) informed consent form or provide equivalent consent per food and drug administration guidelines on covid-19 clinical trials; * has a documented, laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection as determined by polymerase chain reaction, a sars-cov-2 antigen test, or another commercial or public health assay, within 3 days (72 hours) of randomization; * has covid-19 of moderate severity, as defined by the following: positive testing by standard reverse transcription polymerase chain reaction assay or equivalent testing; symptoms of illness with covid-19, which could include any of the following: cough, fever, shortness of breath, chest pain, abdominal pain, nausea/vomiting, diarrhea, body aches, weakness/fatigue, or new loss of taste or smell; clinical signs suggestive of illness with covid-19, such as respiratory rate greater than or equal to 20 breaths per minute, saturation of oxygen greater than 93% on room air at sea level, or heart rate greater than or equal to 90 beats per minute; and no clinical signs indicative of severe or critical severity.

inclusion criteria: - is a male or female greater than or equal to18 years of age at screening; - is willing and able to sign and date (or has a legally authorized representative willing to sign and date) a written (or electronic) informed consent form or provide equivalent consent per food and drug administration guidelines on covid-19 clinical trials; - has a documented, laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection as determined by polymerase chain reaction, a sars-cov-2 antigen test, or another commercial or public health assay, within 3 days (72 hours) of randomization; - has covid-19 of moderate severity, as defined by the following: positive testing by standard reverse transcription polymerase chain reaction assay or equivalent testing; symptoms of illness with covid-19, which could include any of the following: cough, fever, shortness of breath, chest pain, abdominal pain, nausea/vomiting, diarrhea, body aches, weakness/fatigue, or new loss of taste or smell; clinical signs suggestive of illness with covid-19, such as respiratory rate greater than or equal to 20 breaths per minute, saturation of oxygen greater than 93% on room air at sea level, or heart rate greater than or equal to 90 beats per minute; and no clinical signs indicative of severe or critical severity.

inclusion criteria: - is a male or female greater than or equal to18 years of age at screening; - is willing and able to sign and date (or has a legally authorized representative willing to sign and date) a written (or electronic) informed consent form or provide equivalent consent per food and drug administration guidelines on covid-19 clinical trials; - has a documented, laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection as determined by polymerase chain reaction, a sars-cov-2 antigen test, or another commercial or public health assay, within 3 days (72 hours) of randomization; - has covid-19 of moderate severity, as defined by the following: positive testing by standard reverse transcription polymerase chain reaction assay or equivalent testing; symptoms of illness with covid-19, which could include any of the following: cough, fever, shortness of breath, chest pain, abdominal pain, nausea/vomiting, diarrhea, body aches, weakness/fatigue, or new loss of taste or smell; clinical signs suggestive of illness with covid-19, such as respiratory rate greater than or equal to 20 breaths per minute, saturation of oxygen greater than 93% on room air at sea level, or heart rate greater than or equal to 90 beats per minute; and no clinical signs indicative of severe or critical severity.